Tech Company Financing Transactions
Neurophth Therapeutics Funding Round
On 8/11/2023, Neurophth Therapeutics raised $95 million in Series C investment from CMB International Capital Corporation, Wuhan Optical Valley Health and Guangzhou Jinkong Fund.
Transaction Overview
Company Name
Announced On
8/11/2023
Transaction Type
Venture Equity
Amount
$95,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to accelerate clinical trials for its core products, enhancing its R&D capabilities and expanding its pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3rd Floor Building B1 Optics Valley Biological City No.666 G C270-C271
Wuhan Hubei Province, Undisclosed
China
Wuhan Hubei Province, Undisclosed
China
Phone
Website
Email Address
Overview
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Li Bin
Chief Executive Officer
Alvin Luk
Chief Financial Officer
Su Zhang
Chief Operating Officer
Xin Zhang
Chief Scientific Officer
Qiutang Li
Chief Technical Officer
Bose Kalampanayil
Co-Founder
Dabo Cai
General Manager
Su Xiao
Vice President
Luke Li
VP - Human Resources
Jane Yang
VP - Regulatory Affairs
Cao Yang
Browse more venture capital transactions:
Prev: 8/11/2023: Endear Health venture capital transaction
Next: 8/11/2023: InnerSpace venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs